Novel approach to cardiovascular diseases: A promising probability of (pro)renin receptor [(P)RR]

Current Pharmaceutical Design

Volumn 20, Issue 14, 2014, Pages 2371-2376

  Ando, Takashi ^a   Ichihara, Atsuhiro ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

(Pro)renin receptor; Direct renin inhibitor

Indexed keywords

BIOLOGICAL MARKER; PRORENIN; PRORENIN RECEPTOR; RENIN; RENIN INHIBITOR; CARDIOTONIC AGENT; CELL SURFACE RECEPTOR; PROTEIN BINDING; PROTEIN PRECURSOR;

CARDIOVASCULAR DISEASE; CIRCULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; PROTEIN BINDING; PROTEIN PRECURSORS; RECEPTORS, CELL SURFACE; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84903701203     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990472     Document Type: Review

References (63)

1. Sealey JE, Glorioso N, Itskovitz J, Laragh JH. Prorenin as a reproductive hormone. New form of the renin system. Am J Med 1986; 81: 1041-6.
2. Derkx FH, Schalekamp MA. Human prorenin: pathophysiology and clinical implications. Clin Exp Hypertens A 1988; 10: 1213-25.
3. Leckie BJ, Birnie G, Carachi R. Renin in Wilms' tumor: prorenin as an indicator. J Clin Endocrinol Metab 1994; 79: 1742-6.
4. Volpe M, Battistoni A, Chin D, Rubattu S, Tocci G. Renin as a biomarker of cardiovascular disease in clinical practice. Nutr Metab Cardiovasc Dis 2012; 22: 312-7.
5. Schweda F, Friis U, Wagner C, Skott O, Kurtz A. Renin release. Physiology (Bethesda) 2007; 22: 310-9.
6. Deinum J, Rønn B, Mathiesen E, Derkx FH, Hop WC, Schalekamp MA. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999; 42: 1006-10.
7. Ringholm L, Pedersen-Bjergaard U, Thorsteinsson B, Boomsma F, Damm P, Mathiesen ER. A high concentration of prorenin in early pregnancy is associated with development of pre-eclampsia in women with type 1 diabetes. Diabetologia 2011; 54: 1615-9.
8. Watanabe N, Bokuda K, Fujiwara T, et al. Soluble (pro)renin receptor and blood pressure during pregnancy: a prospective cohort study. Hypertension 2012; in press.
9. Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-9.
10. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-104.
11. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med 1993; 329: 616-9.
12. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-9.
13. Parikh NI, Gona P, Larson MG, et al. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 2007; 28: 2644-52.
14. Daimon M, Konta T, Oizumi T, et al. Higher plasma renin activity is a risk factor for total mortality in older Japanese individuals: the Takahata study. Metabolism 2012; 61: 504-11.
15. Verma S, Gupta M, Holmes DT, et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J 2011; 32: 2135-42.
16. Katayama T, Nakashima H, Furudono S, Honda Y, Suzuki S, Yano K. Evaluation of neurohumoral activation (adrenomedullin, BNP, catecholamines, etc.) in patients with acute myocardial infarction. Intern Med 2004; 43: 1015-22.
17. Rouleau JL, Packer M, Moyé L, et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-91.
18. Vantrimpont P, Rouleau JL, Ciampi A, et al. Two-year time course and significance of neurohumoral activation in the Survival and Ventricular Enlargement (SAVE) Study. Eur Heart J 1998; 19: 1552-63.
19. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in VHeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 1993; 87: VI40-8.
20. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292-9.
21. Masson S, Solomon S, Angelici L, et al. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 2010; 16: 964-70.
22. Suzuki F, Hayakawa M, Nakagawa T, et al. Human prorenin has "gate and handle" regions for its non-proteolytic activation. J Biol Chem 2003; 278: 22217-22.
23. Fukamizu A, Nishi K, Cho T, et al. Structure of the rat renin gene. J Mol Biol 1988; 201: 443-50.
24. Inagami T. Purification of renin and prorenin. Hypertension 1991; 18: 241-51.
25. Morris BJ. Molecular biology of renin. I: Gene and protein structure, synthesis and processing. J Hypertens 1992; 10: 209-14.
26. Baxter JD, James MN, Chu WN, et al. The molecular biology of human renin and its gene. Yale J Biol Med 1989; 62: 493-501.
27. Heinrikson RL, Hui J, Zürcher-Neely H, Poorman RA. A structural model to explain the partial catalytic activity of human prorenin. Am J Hypertens 1989; 2: 367-80.
28. Shiratori Y, Nakagawa S, Hori H, Murakami K, Umeyama H. Protein modeling of human prorenin using the molecular dynamics method. J Mol Graph 1990; 8: 163-7.
29. Suzuki F, Hatano Y, Nakagawa T, et al. Non-proteolytic activation of human prorenin by anti-prorenin prosegment (pf#1: 1P-15P) antiserum. Biosci Biotechnol Biochem 1999; 63: 550-4.
30. Ichihara A, Hayashi M, Kaneshiro Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-35.
31. Ichihara A, Suzuki F, Nakagawa T, et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950-61.
32. Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H. Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 1998; 16: 853-62.
33. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-7.
34. Krop M, Danser AH. Circulating versus tissue renin-angiotensin system: on the origin of (pro)renin. Curr Hypertens Rep 2008; 10: 112-8.
35. Krop M, de Bruyn JH, Derkx FH, Danser AH. Renin and prorenin disappearance in humans post-nephrectomy: evidence for binding?. Front Biosci 2008; 13: 3931-9.
36. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-27.
37. Nabi AH, Kageshima A, Uddin MN, Nakagawa T, Park EY, Suzuki F. Binding properties of rat prorenin and renin to the recombinant rat renin/prorenin receptor prepared by a baculovirus expression system. Int J Mol Med 2006; 18: 483-8.
38. Krop M, Lu X, Danser AH, Meima ME. The (pro)renin receptor. A decade of research: what have we learned?. Pflugers Arch 2012.
39. Nguyen G, Bouzhir L, Delarue F, Rondeau E, Sraer JD. [Evidence of a renin receptor on human mesangial cells: effects on PAI1 and cGMP]. Nephrologie 1998; 19: 411-6.
40. Sakoda M, Ichihara A, Kaneshiro Y, et al. (Pro)renin receptormediated activation of mitogen-activated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007; 30: 1139-46.
41. Saris JJ, 't Hoen PA, Garrelds IM, et al. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006; 48: 564-71.
42. Advani A, Kelly DJ, Cox AJ, et al. The (Pro)renin receptor: sitespecific and functional linkage to the vacuolar H+-ATPase in the kidney. Hypertension 2009; 54: 261-9.
43. Huang Y, Noble NA, Zhang J, Xu C, Border WA. Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007; 72: 45-52.
44. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-13.
45. Kaneshiro Y, Ichihara A, Takemitsu T, et al. Increased expression of cyclooxygenase-2 in the renal cortex of human prorenin receptor gene-transgenic rats. Kidney Int 2006; 70: 641-6.
46. Schefe JH, Neumann C, Goebel M, et al. Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. J Hypertens 2008; 26: 1787-94.
47. Schefe JH, Menk M, Reinemund J, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99: 1355-66.
48. Kinouchi K, Ichihara A, Sano M, et al. The (pro)renin receptor/ ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circ Res 2010; 107: 30-4.
49. Oshima Y, Kinouchi K, Ichihara A, et al. Prorenin receptor is essential for normal podocyte structure and function. J Am Soc Nephrol 2011; 22: 2203-12.
50. Cruciat CM, Ohkawara B, Acebron SP, et al. Requirement of prorenin receptor and vacuolar H+-ATPase-mediated acidification for Wnt signaling. Science 2010; 327: 459-63.
51. Sihn G, Rousselle A, Vilianovitch L, Burckle C, Bader M. Physiology of the (pro)renin receptor: Wnt of change?. Kidney Int 2010; 78: 246-56.
52. Müller DN, Derer W, Dechend R. Aliskiren--mode of action and preclinical data. J Mol Med (Berl) 2008; 86: 659-62.
53. Ganten D, Wagner J, Zeh K, et al. Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes. Proc Natl Acad Sci USA 1992; 89: 7806-10.
54. Wellner M, Dechend R, Park JK, et al. Cardiac gene expression profile in rats with terminal heart failure and cachexia. Physiol Genomics 2005; 20: 256-67.
55. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17: 1-7.
56. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in doubletransgenic rats. Hypertension 2005; 46: 569-76.
57. Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-6.
58. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Contribution of nonproteolytically activated prorenin in glomeruli to hypertensive renal damage. J Am Soc Nephrol 2006; 17: 2495-503.
59. Ichihara A, Kaneshiro Y, Takemitsu T, et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47: 894-900.
60. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol 2008; 19: 743-8.
61. Ichihara A. (Pro)renin Receptor and Vacuolar H(+)-ATPase. Keio J Med 2012; 61: 73-8.
62. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, Investigators AS. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-46.
63. McMurray JJ, Abraham WT, Dickstein K, Køber L, Massie BM, Krum H. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012; 14: 341-3.